Compare Bristol-Myers Squibb Co (BMY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MasterCard Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B), while MasterCard Inc trades at $558.35 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 3.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MA | |
|---|---|---|
Market Cap | $129.94B | $491.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $598.96 |
52-Week Low | $42.60 | $471.55 |
Enterprise Value | $163.92B | $504.86B |
Dividend Yield | 3.96% | 0.62% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Mastercard (MA) trades at $563.17, showing stability with a slight 0.04% daily gain. The stock exhibits strong fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and maintains robust profitability with a 46.34% net income margin. Technical indicators signal a bullish trend, supported by moving averages, while analyst consensus is overwhelmingly positive with a $660.85 price target. Recent news highlights institutional acquisitions and strategic initiatives in AI and digital inclusion.
Outlook remains favorable driven by consistent earnings beats and revenue growth, though risks include competitive pressures from emerging payment technologies like stablecoins and high valuation multiples. The stock presents a growth opportunity with solid institutional backing, but investors should monitor execution on innovation and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
